510(k) · Cleared
ClearedCobas Integra Glucose HK Gen. 3 Test System
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Roche Diagnostics Corp. · CFR Hexokinase, Glucose
Cleared on May 17, 2006 as substantially equivalent to K972250 (Roche Diagnostic Systems, Inc., 1997) after a 30-day review. Its family tree reaches back 2 generations to 1984. 1 later device descends from it.
- Decided
- May 17, 2006
- Review
- 30 days
- Class
- Class II
- Product code
- CFR
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 2 generations to K842280 (1984). 4 ancestors in all. 1 later device descends from it, 1 citing it directly.
- Root · 2 generations backK842280 TDX DigitoxinAbbott Laboratories · 1984
- 1 generation backK972250 Roche Cobas Integra Reagent Cassettes & Ancillary ReagentsRoche Diagnostic Systems, Inc. · 1997 · Recalled
- This deviceK061048 Cobas Integra Glucose HK Gen. 3 Test SystemRoche Diagnostics Corp. · 2006
- Descendant · cites it directly · 0 of its ownK092603 Cobas Integra Glucose HK Gen 3 AssayRoche Diagnostics · 2009
Most influential descendants
Showing 1 of 1 · See all- K092603Cobas Integra Glucose HK Gen 3 AssayRoche Diagnostics · 2009 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K842280 | TDX Digitoxin | Abbott Laboratories | 1984 | — |
| −1 | K972250 | Roche Cobas Integra Reagent Cassettes & Ancillary Reagents | Roche Diagnostic Systems, Inc. | 1997 | 1 |
| 0 (this device) | K061048 | Cobas Integra Glucose HK Gen. 3 Test System | Roche Diagnostics Corp. | 2006 | — |
| +1 | K092603 | Cobas Integra Glucose HK Gen 3 Assay | Roche Diagnostics | 2009 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1991 | 1 | 0 |
| 1995 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2009 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in CFR? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new CFR device
- #1 K253490 Glucose HK Gen.3; ONLINE DAT Methadone II…score 11.4 · 3 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K972250 | Roche Cobas Integra Reagent Cassettes & Ancillary ReagentsSummary page 1…ebrospinal fluid (CSF) on COBAS IN'TEGRA systems. Predicate We claim substantial equivalence to the COBAS INTEGRA Glucose IHK Device Liquid cleared as K972250. Substantial The table below indicates the similarities between the modified COBAS equivalency - INTEGRA Glucose UK Gen… | 1997 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K092603 | Cobas Integra Glucose HK Gen 3 Assay | 2009 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 22 years and passes through 3 companies; a new generation was cleared every 13.0 years on median.
- 2 of the 4 ancestors have a recall of any class.
- Of its descendants, K092603 (Roche Diagnostics, 2009) has gone furthest, with 0 descendants of its own.
- 5 other devices also cite its predicate K972250.
How does its category compare?
All CFR devicesCFR Hexokinase, Glucose: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · CFR
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · CFR
115in 2012
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · CFR
1in 2016
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · CFR
16in 2025
MAUDE reports naming product code CFR, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 1 | — | 0 | 1 |
| 2008 | 5 | 182 | 7 | 2 |
| 2009 | 3 | 101 | 1 | 7 |
| 2010 | 0 | — | 0 | 11 |
| 2011 | 3 | 316 | 0 | 43 |
| 2012 | 4 | 115 | 1 | 49 |
| 2013 | 1 | — | 0 | 36 |
| 2014 | 1 | — | 1 | 2 |
| 2015 | 0 | — | 0 | 3 |
| 2016 | 2 | — | 1 | 1 |
| 2017 | 1 | — | 0 | 13 |
| 2018 | 0 | — | 0 | 8 |
| 2019 | 1 | — | 0 | 10 |
| 2020 | 0 | — | 0 | 4 |
| 2021 | 0 | — | 0 | 5 |
| 2022 | 1 | — | 0 | 3 |
| 2023 | 0 | — | 0 | 29 |
| 2024 | 0 | — | 0 | 15 |
| 2025 | 1 | — | 0 | 16 |
| 2026 | 1 | — | 0 | — |
What is it indicated for?
In vitro test for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid (CSF) on COBAS INTEGRA systems.
Glucose measurements are used in diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and pancreatic islet cell tumors.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K061048 · printed Nov 4, 2026
Cite this page
510(k) Report. “K061048: Cobas Integra Glucose HK Gen. 3 Test System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K061048
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026